arrow
M

Michael Wang

the university of north carolina at chapel hill
H指数:94
被引数:4.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cardiac fibroblast deletion of PTBP1 modulates the profibrotic response by alternative splicing

心脏成纤维细胞中PTBP1的缺失通过选择性剪接调节促纤维化反应

2026-09-110
OAAI
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study

伊布替尼联合维奈克拉用于复发/难治性套细胞淋巴瘤:SYMPATICO III期研究的最终分析

2026-08-210
OAAI
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations

一线伊布替尼联合维奈克拉治疗≥65岁或TP53突变的外套细胞淋巴瘤(非母细胞样型)

Blood
IF23.1
2026-07-030
OA
BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance

BRG1介导的铁死亡抑制是BTK抑制剂耐药性的基础

2026-07-020
OAAI
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study

lisocabtagene maraleucel在TRANSCEND NHL 001研究中复发/难治性LBCL的五年生存结局

Blood
IF23.1
2026-06-050
OAAI
Non-contact laser polishing and reconstruction towards high-efficiency all-perovskite tandem solar cells

非接触激光抛光与重构技术在高效率全钙钛矿叠层太阳能电池中的应用

2026-05-080
OAAI
A CONTEMPORARY ANALYSIS OF POSITIVE SURGICAL MARGIN LENGTH AND ONCOLOGIC OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM AN INSTITUTIONAL REGISTRY WITH LONG-TERM FOLLOW UP

当代正手术切缘长度与根治性前列腺切除术后肿瘤学结局的分析:来自具有长期随访的机构注册登记研究结果

2026-05-010
PRE
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

艾美珠单抗(Emicizumab)在参与ATHN 7血友病自然史研究(Haemophilia Natural History Study)的A型血友病患者中的安全性与有效性。

2025-11-110
OAAI